
|Videos|May 18, 2023
ER+, HER2- Advanced Breast Cancer: Clinical Implications of the EMERALD Trial
Following their discussion of the EMERALD trial and elacestrant with Virginia Kaklamani, MD, DSc, the Oncology Brothers share clinical implications of the EMERALD trial to practice and look toward the future of ER+, HER2- advanced breast cancer management.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Allogeneic CD70 CAR T-Cell Therapy Shows Activity in Refractory Kidney Cancer
2
Indefinite Myeloma Maintenance Shows No OS Benefit vs 2-Year Duration
3
Pembrolizumab Plus Denosumab Shows Activity in Pretreated Kidney Cancer
4
Final RELEVANCE Data Affirm R2 as Chemo-Free Alternative in Untreated FL
5


























